DPM produces approximately 40% of Dechra’s pharmaceuticals and manufactures for a limited number of third parties on a contract basis. It’s objectives are to produce Dechra’s product range efficiently to the highest quality standards, to maintain a reliable supply chain and to contribute profit to the business through third party manufacturing.
A total of 876 employees work in Manufacturing.
Skipton, Bladel and Zagreb sites include Pharmaceutical Development, Quality Control (QC) and Stability Testing and Validation Laboratories.
The site at Skipton offers a comprehensive range of manufacturing and packing services, principally for CAP. It is a centre of excellence in solid forms for tablets and capsules, liquids, creams, ointment products and terminal sterilisation.
Bladel, the Netherlands
The site at Bladel manufactures water soluble powder and premix products for food producing animals in large-scale batches. It is also a centre for aseptic filling and for sterile injectables for both FAP and CAP.
It produces and develops egg based vaccines. It also produces liquids in various scales and formats and is currently being expanded to be a second source of solid dose tablets.
Fort Worth, Texas USA
This site manufactures solid dose, liquids, creams and ointments for the North American market.
Melbourne, Florida USA
It is a centre of excellence in manufacturing palatable and chewable tablets.
The following manufacturing sites are managed by our DVP International business:
This site produces a wide range of vaccines for multi species predominately for South America and selected export markets.
This site produces a broad portfolio of dosage types for the Australian and New Zealand markets including tablets and liquids.